Lloyd Klickstein
Fondatore presso Versanis Bio, Inc.
Posizioni attive di Lloyd Klickstein
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
Versanis Bio, Inc.
 Versanis Bio, Inc. BiotechnologyHealth Technology Part of Eli Lilly & Co., Versanis Bio, Inc. is a clinical-stage biopharmaceutical company. The company is based in New York, NY. The company was founded by Lloyd Klickstein. Mark E. Pruzanski has been the CEO of the company since 2021. Versanis Bio was acquired by Eli Lilly & Co. on August 14, 2023 for $1,925 million. | Fondatore | 01/02/2021 | - |
| Direttore Tecnico/Scientifico/R&S | 01/04/2022 | - | |
| Presidente | 20/07/2022 | - | |
| Amministratore Delegato | 01/02/2021 | 01/04/2022 |
Storia della carriera di Lloyd Klickstein
Precedenti posizioni note di Lloyd Klickstein
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
Blade Therapeutics, Inc.
 Blade Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Blade Therapeutics, Inc. offers anti-fibrotic therapies to meet unserved patient needs. Its product portfolio is to address various fibrotic diseases and their underlying pathophysiology. The company was founded by Hal Dietz and Wendye R. Robbins and is headquartered in South San Francisco, CA. | Direttore/Membro del Consiglio | 01/05/2019 | 01/02/2023 |
| ADICET BIO, INC. | Corporate Officer/Principal | 01/05/2019 | 19/02/2021 |
Novartis Institutes for Biomedical Research, Inc.
 Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institutes for Biomedical Research, Inc. conducts biomedical researches. It focuses in the areas of oncology, ophthalmology, diabetes, musculoskeletal disorders, neuroscience, and cardiovascular conditions, other focus areas include discovery chemistry, biologics, pathway biology, and translational medicine. The company was founded on September 10, 2002 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - | - |
| ADICET BIO, INC. | Direttore Tecnico/Scientifico/R&S | 14/05/2019 | 15/09/2020 |
| Corporate Officer/Principal | 15/09/2020 | - |
Formazione di Lloyd Klickstein
| Tufts University | Undergraduate Degree |
| Harvard University | Doctorate Degree |
Statistiche
Distribuzione geografica
| Stati Uniti | 8 |
Posizioni
| Corporate Officer/Principal | 3 |
| Chief Tech/Sci/R&D Officer | 2 |
| Undergraduate Degree | 1 |
Settori
| Health Technology | 4 |
| Consumer Services | 3 |
| Commercial Services | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| ADICET BIO, INC. | Health Technology |
| Aziende private | 4 |
|---|---|
resTORbio, Inc.
 resTORbio, Inc. BiotechnologyHealth Technology resTORbio, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the development and commercialization of medicines for aging-related diseases and conditions. It offers an immunotherapy under the TORC1 program. The company was founded by Chen Schor and Joan Mannick on July 5, 2016 and is headquartered in Boston, MA. | Health Technology |
Blade Therapeutics, Inc.
Blade Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Blade Therapeutics, Inc. offers anti-fibrotic therapies to meet unserved patient needs. Its product portfolio is to address various fibrotic diseases and their underlying pathophysiology. The company was founded by Hal Dietz and Wendye R. Robbins and is headquartered in South San Francisco, CA. | Commercial Services |
Novartis Institutes for Biomedical Research, Inc.
Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institutes for Biomedical Research, Inc. conducts biomedical researches. It focuses in the areas of oncology, ophthalmology, diabetes, musculoskeletal disorders, neuroscience, and cardiovascular conditions, other focus areas include discovery chemistry, biologics, pathway biology, and translational medicine. The company was founded on September 10, 2002 and is headquartered in Cambridge, MA. | Commercial Services |
Versanis Bio, Inc.
Versanis Bio, Inc. BiotechnologyHealth Technology Part of Eli Lilly & Co., Versanis Bio, Inc. is a clinical-stage biopharmaceutical company. The company is based in New York, NY. The company was founded by Lloyd Klickstein. Mark E. Pruzanski has been the CEO of the company since 2021. Versanis Bio was acquired by Eli Lilly & Co. on August 14, 2023 for $1,925 million. | Health Technology |
- Borsa valori
- Insiders
- Lloyd Klickstein
- Esperienza
